This acquisition will help generate data from over four million members of MyHealthTeams’ opted-in patient universe.
Swoop announced its acquisition of MyHealthTeam, creator of one of the largest opted-in patient social networks in the US. The companies share a vision of making vetted information more available for patients, as well as providing them with peers and a community for support.
“We acquired MyHealthTeam–a leading opted-in patient universe–because of their adept ability to build trusted, condition-specific patient communities at scale,” said Ron Elwell, founder and CEO of Swoop, in a press release. “This acquisition builds on our already strong position…by strategically 'bookending' privacy-compliant marketing, we will be able to provide even further value to pharma brands and patients…Together, we help pharma brands build deep and authentic relationships in the patient community, and reinforce that messaging with treating physicians, and in every channel across the web and TV.”1
MyHealthTeam leverages information from four million of patients spanning across chronic and rare diseases areas like Alzheimer’s, COPD, diabetes, various cancers, and more.2 The patient social networks not only have virtual communities to elicit insights from but also provide data, which is privacy compliant, that can help healthcare marketers understand patient needs from a new perspective. This has been a focus for Swoop since spinning off from Real Chemistry in early September 2024.3
The two companies hope that the combination of this data and insights into the more than 62 communities will inform more omnichannel marketing decisions—fostering stronger connections between patients, brands, and healthcare providers. This would help keep the balance of targeted marketing while maintaining patient privacy, a common challenge for pharmaceutical marketers.
Aside from the ability to share their experiences and ailments with other members of their community, MyHealthTeam members can also find support and information. “More than anything else, our members facing chronic and rare conditions want to know what’s coming around the next corner and how they can best prepare for it," said Eric Peacock, co-founder and CEO of MyHealthTeam. “They connect and chat with other members, they consume the medically-approved articles and videos we create for them, and now we can bring Swoop’s vast depth of claims data, machine learning and AI capabilities to bear in delivering them information that is personalized based on where they are in their patient journey.”1
Plans to launch additional communities in many more conditions this year are already in the works.
“Our mission at Swoop has always been to harness the power of data and AI to create impactful, privacy-first solutions that connect patients and healthcare providers,” Scott Rines, president of Swoop added, “By integrating MyHealthTeam’s vibrant social communities into our omnichannel marketing suite, we’re advancing [that mission] in a monumental way. Together, we are bridging the gap between healthcare brands and patients to create more impactful, targeted, and seamless engagement strategies to ultimately improve patients’ outcomes.”1
Financial details of this acquisition have not been disclosed.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.